Differential depth of treatment response required for optimal outcome in patients with blast phase versus chronic phase of chronic myeloid leukemia

por Chen, Z, Medeiros, L J, Kantajian, H M, Zheng, L, Gong, Z, Patel, K P, Xiong, H, Wang, W, Cortes, J E, Hu, S
Publicado 2017

Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials

por le Coutre, P D, Hughes, T P, Mahon, F-X, Kim, D-W, Steegmann, J L, Shah, N P, Gooden, K, Wallis, N, Cortes, J E
Publicado 2016

Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia

por Gong, Z, Medeiros, L J, Cortes, J E, Zheng, L, Khoury, J D, Wang, W, Tang, G, Loghavi, S, Luthra, R, Yang, W, Kantarjian, H M, Hu, S
Publicado 2017

Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy

por Chen, Z, Wang, W, Cortes, J E, Liu, E, Miranda, R N, Zhao, C, Yuan, J, Lu, X, Yang, W, Ameri, M D, Kantarjian, H M, Medeiros, L J, Hu, S
Publicado 2016

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

por Hochhaus, A., Baccarani, M., Silver, R. T., Schiffer, C., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Deininger, M. W., Guilhot, F., Hjorth-Hansen, H., Hughes, T. P., Janssen, J. J. W. M., Kantarjian, H. M., Kim, D. W., Larson, R. A., Lipton, J. H., Mahon, F. X., Mayer, J., Nicolini, F., Niederwieser, D., Pane, F., Radich, J. P., Rea, D., Richter, J., Rosti, G., Rousselot, P., Saglio, G., Saußele, S., Soverini, S., Steegmann, J. L., Turkina, A., Zaritskey, A., Hehlmann, R.
Publicado 2020